Member Info for KingHomerJ

Agreed….looks like 1.25 is resistance the could move very quick to the 1.6 -1.80 range…..

All very positive this rerate as the higher we get before the heavy news flow the better.

Hopefully get back to the MC we deserve vs peers most of which have zero revenue and a limited pipeline and growth which Laura correctly pointed out.

3 years ago PYC was sitting at a 16mil MC and out revenue, pipeline and prostate dosing tool are multiples of what they were.

All very encouraging

The key thing especially with the Prostate Cancer Dosing application the company will get real time live clinical data.

This is huge for the company.

Yes DeBull there was £100k in block buying....which is a statement

I think £100k in block buys is a very different signal than last weeks rise….

As mentioned it’s possible a TR1 is on route if it’s the same buyer…which does look like it

As the trades show this morning over 5/6 Trades someone has picked up over £100,000....

That's confidence..... and if it is one individual / company then i would expect a TR1 as this is well over the threshold of 3%

This could get interesting very very quickly...

Trench - this is a very valid point and something I thought of myself about the unusual lack of coms

Jarrii.

Its not and intention is FACT - read the RNS's

The tool is already in a trial with Blackpool NHS teaching Hospital which is also with Beyond Blood Tech... Which is Grant funded

Beyond Bloods Company Value sits at around 33 million

and the tool is also integrated into the DosemeRX software which has 1000's of licenses globally.

so frankly Jarri you are talking absolute nonsense

I believe you are bang on and I believe we will get more contracts from them….as previously mentioned in presentation various contracts / phases where waiting on data to be returned during / after trials…..

Correct Sam - it is huge huge news….these companies are getting snapped up.

Boehringer Ingelheim will be gaining access to Synaffix’s antibody-drug conjugate (ADC) technology through a licensing agreement worth over $1.3bn

https://pmlive.com/pharma_news/boehringer-gains-access-to-synaffixs-adc-technology-through-1-3bn-licensing-deal/

We have a better peer reviewed platform also which is far more than just ACDS

Nothing….missing nothing that’s the points….its so undervalued.

Very good summary…

In addition there is the New biostats Revenue arm to start kicking offf and generating revenue….

Prostate Cancer Dosing Trial started last week….

And Joint Venture partner is Pfizer

Huge for PYC as PYC is working in the ADC space as per December RNC

Pfizer is expanding its collaboration with the start-up PostEra, which applies artificial intelligence to medicinal chemistry. The pharmaceutical giant will pay the smaller firm up to $350 million to use software models to design new small molecules as well as antibody-drug conjugates, or ADCs.

ADCs are new territory within the PostEra-Pfizer partnership. The two companies have been working together since late 2020, when Pfizer tapped 1-year-old PostEra to design small molecules using machine learning for an undisclosed amount of money. Just over a year later, Pfizer expanded the partnership to antivirals and cancer drugs, paying PostEra $13 million up front and promising up to $248 million in milestone payments. The new deal includes $12 million up front.

https://cen.acs.org/business/start-ups/Pfizer-doubles-down-AI-partnership/103/web/2025/01

And another 2 peer reviews to come......

Numab who got bought by Johnson and Johnson for 1.25 billion

Merck?

Bicycle?

3 peer review papers from Major Pharmas is basically a gold stamp of approval to any company in drug development for modelling which is not a FDA requirement.....

Also stated a few months ago that all recent news was in the pipeline. (And more to follow)

There is more than One peer Review to come…..

Another one due shortly

Agreed....in current form PYC should be sitting at the 5p - 6p range (10 -12 Million MC)

Astellas being a Top Pharma worth £17 Billion is Great News

With there prostate cancer drug being a Joint Venture with Pfizer

That’s a huge Buy - as stated just under 3%

Maybe a TR1 if they are already holding

Jarri - this is factually incorrect and you know this….